Navigation Links
Drug Screen (Nonforensic), Comprehensive, Serum & Urine

ProductsDrug Screen (Nonforensic), Comprehensive, Serum & Urine
Company ARUP Laboratories
Item Drug Screen (Nonforensic), Comprehensive, Serum & Urine
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Automatic Tangent Screen
2. 1-Meter Roll-Up Tangent Screen
3. Welch Allyn Suresight™ Vision Screener (English)
4. ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens
5. Topcon SS-3 Screenoscope
6. Screenline LCD Monitors
7. DiaScreen 50 Urine Chemistry Analyzer
8. Hema Screen™
9. QuickScreen™ Multi-Panel Dip Card
10. QuickScreen™ At Home Drug Test
11. SureStep™ Drug Screen Tests - One-Step Immunoassays (Morphine II)
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 1Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 4Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 1Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 2Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 3Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 4Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 5Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 6Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results 6022 7